The FDA has approved the first dual-agent eye drop to treat presbyopia, a condition that causes gradual loss of near vision in adults.

Life Biosciences will test its gene therapy designed to partially reset a cell’s age and potentially reverse vision loss in patients with glaucoma and NAION.

The Phase I trial will recruit participants who have been diagnosed with non-arteritic anterior ischaemic optic neuropathy ...

The FDA approved a larger nelarabine vial to improve dosing flexibility and simplify treatment for adult and pediatric ...

A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including ...

The U.S. Food and Drug Administration (FDA) has approved a drug to control seizures in dogs with idiopathic epilepsy, a type ...

The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for ...

The FDA approved re-administration of iDose TR for patients with healthy corneas, enhancing treatment flexibility for ...

The FDA approved Yuvezzi, an eye drop for the treatment of presbyopia, with broad U.S. availability expected in the second quarter, according to a press release from Tenpoint Therapeutics. Yuvezzi ...

FDA approves KBroVet chewable tablets for managing canine idiopathic epilepsy.

In early 2025, the FDA was rocked by sweeping layoffs and leadership turnover, raising questions about whether the agency ...

A year after the FDA rejected its drug for kidney dialysis patients, Unicycive Therapeutics could win approval ...